|
|
Blood, 15 January 2008, Vol. 111, No. 2, pp. 732-740.
Prepublished online as a Blood First Edition Paper on October 4, 2007; DOI 10.1182/blood-2007-05-089821.
 Previous Article | Next Article 
Submitted May 9, 2007
Accepted October 1, 2007
Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement
Yuko Kimura, Takashi Miwa, Lin Zhou, and Wen-Chao Song*
Institute for Translational Medicine and Therapeutics, and Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States
* Corresponding author; email: song{at}spirit.gcrc.upenn.edu.
Properdin is a positive regulator of alternative pathway (AP) complement. The current understanding of properdin function is that it facilitates AP complement activation by stabilizing the C3 convertase C3bBb. Properdin-deficient individuals are susceptible to lethal meningococcal infection, but the mechanism of this selective predisposition is not fully understood. By gene targeting in the mouse, we show here that properdin is essential for AP complement activation induced by bacterial lipopolysacharride (LPS) and lipooligosacharride (LOS) and other, but not all, AP complement activators. LPS- and LOS-induced AP complement activation was abolished in properdin-/- mouse serum, and properdin-/- mice were unable to clear Crry-deficient erythrocytes, which are known to be susceptible to AP complement-mediated extravascular hemolysis. In contrast, zymosan- and cobra venom factor-induced AP complement activation, and classical pathway-triggered AP complement amplification were only partially or minimally affected in properdin-/- mice. We further show that the ability of human properdin to restore LPS-dependent AP complement activity in properdin-/- mouse serum correlated with the human properdin-binding affinity of the LPS. These results reveal a novel role of properdin in AP complement initiation and have implications for understanding the selective predisposition of properdin-deficient individuals to meningococcal infection.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. M. Mangsbo, J. Sanchez, K. Anger, J. D. Lambris, K. N. Ekdahl, A. S. Loskog, B. Nilsson, and T. H. Totterman
Complement Activation by CpG in a Human Whole Blood Loop System: Mechanisms and Immunomodulatory Effects
J. Immunol.,
November 15, 2009;
183(10):
6724 - 6732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. K. Banda, B. Levitt, M. J. Glogowska, J. M. Thurman, K. Takahashi, G. L. Stahl, S. Tomlinson, W. P. Arend, and V. M. Holers
Targeted Inhibition of the Complement Alternative Pathway with Complement Receptor 2 and Factor H Attenuates Collagen Antibody-Induced Arthritis in Mice
J. Immunol.,
November 1, 2009;
183(9):
5928 - 5937.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Miwa, L. Zhou, Y. Kimura, D. Kim, A. Bhandoola, and W.-C. Song
Complement-dependent T-cell lymphopenia caused by thymocyte deletion of the membrane complement regulator Crry
Blood,
March 19, 2009;
113(12):
2684 - 2694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Gaarkeuken, M. A. Siezenga, K. Zuidwijk, C. van Kooten, T. J. Rabelink, M. R. Daha, and S. P. Berger
Complement activation by tubular cells is mediated by properdin binding
Am J Physiol Renal Physiol,
November 1, 2008;
295(5):
F1397 - F1403.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D. Ivanovska, P. A. Dimitrova, J. C. Luckett, R. El-Rachkidy Lonnen, W. J. Schwaeble, and C. M. Stover
Properdin Deficiency in Murine Models of Nonseptic Shock
J. Immunol.,
May 15, 2008;
180(10):
6962 - 6969.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
